title: [A case of colon cancer with multiple liver metastases effectively treated with hepatic arterial infusion followed by systemic chemotherapy].
abstract: A 63-year-old female was diagnosed as descending colon cancer with severe liver dysfunction caused by multiple liver metastases. Her performance status (PS) was 3 because of liver dysfunction and high fever. Initially, hepatic arterial infusion (HAI) chemotherapy was started to reduce the size of metastatic tumors and to prevent a liver failure. After 10 courses of HAI chemotherapy, she recovered from liver dysfunction, and CapeOX plus bevacizumab regimen was started. A partial response of metastatic liver tumors was observed after 8 cycles of this regimen and metastatic lung tumors were disappeared. The patient was alive after 12 months with PS 0 and CapeOX was continued.
authors.affiliation: Dept. of Surgical Oncology, Tokyo Medical and Dental University Graduate School.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Yamauchi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Uetake
authors.forename: Koji
authors.initials: K
authors.lastname: Miyazaki
authors.forename: Akifumi
authors.initials: A
authors.lastname: Kikuchi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ono
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kato
authors.forename: Megumi
authors.initials: M
authors.lastname: Ishiguro
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Satoru
authors.initials: S
authors.lastname: Iida
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Higuchi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Enomoto
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sugihara
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000556:secondary*; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab